{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-042660","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.601859+00:00","generated_at":"2026-05-24T09:56:19.705010+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Assembly Biosciences FY 2024 net loss narrows to $40.2M; pipeline advancing with multiple data readouts in 2025","bullets":["Net loss $40.2M ($6.69/share) narrowed from $61.2M ($13.38/share) in 2023; collaboration revenue $28.5M vs $7.2M.","Cash $112.1M at year-end; projected to fund operations into mid-2026.","Received $20.1M equity investment and $10M accelerated funding from Gilead.","Phase 1b data for ABI-4334 (HBV capsid modulator) showed mean 2.9 log10 IU/mL HBV DNA decline in 150mg cohort.","Interim Phase 1b efficacy data for ABI-5366 and ABI-1179 (genital herpes) expected fall 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-042660","json":"https://secwatch.observer/filing/0000950170-25-042660.json","markdown":"https://secwatch.observer/filing/0000950170-25-042660.md","text":"https://secwatch.observer/filing/0000950170-25-042660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017025042660/0000950170-25-042660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017025042660/asmb-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T09:56:19.705010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}